我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中(未招募)
1
33.3%
招募中
Unknown
暂无批准数据
- Researchers from the Chinese Academy of Sciences developed SeNExo, a novel therapeutic agent combining neural stem cell-derived exosomes with ultrasmall nano-selenium particles for treating traumatic brain and spinal cord injuries. - The therapy effectively crosses the blood-brain barrier via APOE-LRP-1 interaction and addresses both oxidative damage through ROS scavenging and neuronal repair through exosome-mediated mechanisms. - In mouse models, SeNExo reduced cerebral lesions, improved spatial learning and memory functions in TBI, and promoted locomotor recovery in spinal cord injury cases. - The treatment demonstrates significant potential by downregulating oxidative stress and apoptosis genes while promoting glial homeostasis and enhancing neuron-glia communication networks.